These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18525007)

  • 1. High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients.
    Bollée G; Anglicheau D; Loupy A; Zuber J; Patey N; Mac Gregor D; Martinez F; Mamzer-Bruneel MF; Snanoudj R; Thervet E; Legendre C; Noël LH
    Clin J Am Soc Nephrol; 2008 Sep; 3(5):1461-8. PubMed ID: 18525007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study.
    Luque Y; Anglicheau D; Rabant M; El Karoui K; Jamme M; Aubert O; Clément R; Noël LH; Bollée G; Brodin-Sartorius A; Martinie M; Kreis H; Timsit MO; Legendre C
    Transpl Int; 2016 Nov; 29(11):1205-1215. PubMed ID: 27529401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of Serial Protocol Biopsies Performed After 1 Year in Predicting Long-Term Kidney Allograft Function According to Histologic Phenotype.
    Zachariah MS; Dwivedi AK; Yip CS; Chang SS; Gundroo A; Venuto RC; Tomaszewski J; Patel SK; Sharma R
    Exp Clin Transplant; 2018 Aug; 16(4):391-400. PubMed ID: 29206090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isometric tubular epithelial vacuolization in renal allograft biopsy specimens of patients receiving low-dose intravenous immunoglobulin for a positive crossmatch.
    Haas M; Sonnenday CJ; Cicone JS; Rabb H; Montgomery RA
    Transplantation; 2004 Aug; 78(4):549-56. PubMed ID: 15446314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive regimen and interstitial fibrosis and tubules atrophy at 12 months postrenal transplant.
    Gelens MA; Steegh FM; van Hooff JP; van Suylen RJ; Nieman FH; van Heurn LW; Peutz-Kootstra CJ; Christiaans MH
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):1010-7. PubMed ID: 22490875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Pooled Immunoglobulin as Treatment of Active Antibody-Mediated Rejection of Transplanted Kidney.
    Furmańczyk-Zawiska A; Urbanowicz A; Perkowska-Ptasińska A; Bączkowska T; Sadowska A; Nazarewski S; Chmura A; Durlik M
    Transplant Proc; 2016 Jun; 48(5):1446-50. PubMed ID: 27496425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of renal transplant histology at three months.
    Kuypers DR; Chapman JR; O'Connell PJ; Allen RD; Nankivell BJ
    Transplantation; 1999 May; 67(9):1222-30. PubMed ID: 10342313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pathological analyses of interstitial fibrosis and tubular atrophy cases after kidney transplantation.
    Shimizu T; Toma H; Hayakawa N; Shibahara R; Ishiyama R; Hayashida A; Fujimori D; Tsunoyama K; Ikezawa E; Kitajima S; Iida S; Ishida H; Tanabe K; Honda K; Koike J
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():26-30. PubMed ID: 26972969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Recipients: Single-Center Experience.
    Nair P; Gheith O; Al-Otaibi T; Mostafa M; Rida S; Sobhy I; Halim MA; Mahmoud T; Abdul-Hameed M; Maher A; Emam M
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):113-119. PubMed ID: 30777534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe antibody-mediated rejection following IVIG infusion in a kidney transplant recipient with BK-virus nephropathy.
    Mainra R; Xu Q; Chibbar R; Hassan A; Shoker A
    Transpl Immunol; 2013 Jun; 28(4):145-7. PubMed ID: 23685054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
    Jordan SC; Tyan D; Stablein D; McIntosh M; Rose S; Vo A; Toyoda M; Davis C; Shapiro R; Adey D; Milliner D; Graff R; Steiner R; Ciancio G; Sahney S; Light J
    J Am Soc Nephrol; 2004 Dec; 15(12):3256-62. PubMed ID: 15579530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of high-dose human immune globulin in highly sensitized patients on the kidney transplant waiting list: one center's experience.
    Gozdowska J; Urbanowicz A; Perkowska-Ptasinska A; Michalska K; Chmura A; Szmidt J; Durlik M
    Transplant Proc; 2009 Oct; 41(8):2997-3001. PubMed ID: 19857660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization.
    Randhawa PS; Saad RS; Jordan M; Scantlebury V; Vivas C; Shapiro R
    Transplantation; 1999 Jan; 67(1):85-9. PubMed ID: 9921801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of histological damage on long-term kidney transplant outcome.
    Nankivell BJ; Fenton-Lee CA; Kuypers DR; Cheung E; Allen RD; O'Connell PJ; Chapman JR
    Transplantation; 2001 Feb; 71(4):515-23. PubMed ID: 11258430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Indication Biopsies ≥5 Years After Kidney Transplant: A Single-Center Experience.
    Tatar E; Simsek C; Tasli F; Cayhan VK; Karatas M; Uslu A
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):265-268. PubMed ID: 28260483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic and Transcriptomic Lymphocytes Changes in Allograft Recipients After Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients.
    Pilon C; Bigot J; Grondin C; Thiolat A; Lang P; Cohen JL; Grimbert P; Matignon M
    Front Immunol; 2020; 11():34. PubMed ID: 32038663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
    Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
    Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
    Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.